I agree. Something that bother me since the announcement of TL results is why the % CKD patients in the BETOnMACE trial is so low. For eGFR < 60, in the Examine trial it is 29.6% (not be able to find breakdown for Elixa trial). I don't know if anyone notice the following on page 8 of the latest MD&A:

"...   The proportion of CKD patients was 11%, lower than anticipated (possibly because of competing trials) which compares to 25-29% from similar DM post-ACS populations.  "

I wonder if the proportion of CKD patients in BETOnMACE trial is similar to that of Examine trial...